![]() | |
Clinical data | |
---|---|
Other names | 6,7,8,9-Tetrahydro-5H-benzocyclohepten-7-ylamine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C11H15N |
Molar mass | 161.248 g·mol−1 |
3D model (JSmol) | |
| |
|
7-AB, also known as 7-amino-6,7,8,9-tetrahydro-5H-benzocycloheptene, is a conformationally restricted analogue of amphetamine related to 2-aminoindane (2-AI) and 2-aminotetralin (2-AT). [1] [2] Unlike amphetamine, 2-AI, and 2-AT, 7-AB did not produce stimulant-type effects in animals. [1] [2] Instead, it caused behavioral disruption and death at higher doses. [2] 6-AB is a positional isomer of 7-AB. [1] [2]
Phenethylamine (PEA) is an organic compound, natural monoamine alkaloid, and trace amine, which acts as a central nervous system stimulant in humans. In the brain, phenethylamine regulates monoamine neurotransmission by binding to trace amine-associated receptor 1 (TAAR1) and inhibiting vesicular monoamine transporter 2 (VMAT2) in monoamine neurons. To a lesser extent, it also acts as a neurotransmitter in the human central nervous system. In mammals, phenethylamine is produced from the amino acid L-phenylalanine by the enzyme aromatic L-amino acid decarboxylase via enzymatic decarboxylation. In addition to its presence in mammals, phenethylamine is found in many other organisms and foods, such as chocolate, especially after microbial fermentation.
MBDB, also known as N-methyl-1,3-benzodioxolylbutanamine or as 3,4-methylenedioxy-N-methyl-α-ethylphenylethylamine, is an entactogen of the phenethylamine, amphetamine, and phenylisobutylamine families related to MDMA. It is known by the street names "Eden" and "Methyl-J".
Phenmetrazine, sold under the brand name Preludin among others, is a stimulant drug first synthesized in 1952 and originally used as an appetite suppressant, but withdrawn from the market in the 1980s due to widespread misuse. It was initially replaced by its analogue phendimetrazine which functions as a prodrug to phenmetrazine, but now it is rarely prescribed, due to concerns of misuse and addiction. Chemically, phenmetrazine is a substituted amphetamine containing a morpholine ring or a substituted phenylmorpholine.
2,5-Dimethoxy-4-ethylamphetamine (DOET) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It is closely related to DOM and is a synthetic analogue of the naturally occurring phenethylamine psychedelic mescaline. The drug acts as a selective agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.
4-Methylaminorex is a stimulant drug of the 2-amino-5-aryloxazoline group that was first synthesized in 1960 by McNeil Laboratories. It is also known by its street name "U4Euh" ("Euphoria"). It is banned in many countries as a stimulant. 4-Methylaminorex has effects comparable to methamphetamine but with a longer duration.
Hordenine is an alkaloid of the phenethylamine class that occurs naturally in a variety of plants, taking its name from one of the most common, barley. Chemically, hordenine is the N-methyl derivative of N-methyltyramine, and the N,N-dimethyl derivative of the well-known biogenic amine tyramine, from which it is biosynthetically derived and with which it shares some pharmacological properties. As of September 2012, hordenine is widely sold as an ingredient of nutritional supplements, with the claims that it is a stimulant of the central nervous system, and has the ability to promote weight loss by enhancing metabolism. In experimental animals, given sufficiently large doses parenterally, hordenine does produce an increase in blood pressure, as well as other disturbances of the cardiovascular, respiratory, and nervous systems. These effects are generally not reproduced by oral administration of the drug in test animals, and virtually no scientific reports of the effects of hordenine in human beings have been published.
Naphthylaminopropane, also known as naphthylisopropylamine (NIPA), is an experimental drug of the amphetamine and naphthylaminopropane families that was under investigation for the treatment of alcohol and stimulant addiction.
para-Chloroamphetamine (PCA), also known as 4-chloroamphetamine (4-CA), is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) and serotonergic neurotoxin of the amphetamine family. It is used in scientific research in the study of the serotonin system, as a serotonin releasing agent (SRA) at lower doses to produce serotonergic effects, and as a serotonergic neurotoxin at higher doses to produce long-lasting depletions of serotonin.
MDAI, also known as 5,6-methylenedioxy-2-aminoindane, is an entactogen drug of the 2-aminoindane group which is related to MDMA and produces similar subjective effects.
A monoamine releasing agent (MRA), or simply monoamine releaser, is a drug that induces the release of one or more monoamine neurotransmitters from the presynaptic neuron into the synapse, leading to an increase in the extracellular concentrations of the neurotransmitters and hence enhanced signaling by those neurotransmitters. The monoamine neurotransmitters include serotonin, norepinephrine, and dopamine; MRAs can induce the release of one or more of these neurotransmitters.
2-Aminoindane (2-AI) is an aminoindane and research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a designer drug. It acts as a selective substrate for NET and DAT.
A serotonin releasing agent (SRA) is a type of drug that induces the release of serotonin into the neuronal synaptic cleft. A selective serotonin releasing agent (SSRA) is an SRA with less significant or no efficacy in producing neurotransmitter efflux at other types of monoamine neurons, including dopamine and norepinephrine neurons.
2-Aminotetralin (2-AT), also known as 1,2,3,4-tetrahydronaphthalen-2-amine (THN), is a stimulant drug with a chemical structure consisting of a tetralin group combined with an amine.
3-Methoxyamphetamine (3-MA), also known as meta-methoxyamphetamine (MMA), is a monoamine releasing agent (MRA) of the amphetamine family. It is a positional isomer of para-methoxyamphetamine.
2-Amino-1,2-dihydronapthalene is a stimulant drug. It is a rigid analogue of phenylisobutylamine and substitutes for amphetamine in rat drug discrimination tests, although at approximately one-fourth the potency.
1-Phenylpiperazine is a simple chemical compound and drug featuring a phenyl group bound to a piperazine ring. The suffix ‘-piprazole’ is sometimes used in the names of drugs to indicate they belong to this class.
3,4-Methylenedioxycathinone, also known as β-keto-3,4-methylenedioxyamphetamine (βk-MDA), is an entactogen and stimulant drug of the phenethylamine, amphetamine, and cathinone families. It is the β-keto analogue of MDA.
N,N-Dimethyldopamine (DMDA) is an organic compound belonging to the phenethylamine family. It is related structurally to the alkaloid epinine (N-methyldopamine) and to the major neurotransmitter dopamine (of which it is the N,N-dimethylated analog). Because of its structural relationship to dopamine, DMDA has been the subject of a number of pharmacological investigations. DMDA has been detected in Acacia rigidula.
Ethylnaphthylaminopropane is a monoamine releasing agent (MRA) of the amphetamine and naphthylaminopropane families that is related to naphthylaminopropane and methamnetamine. It acts specifically as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). However, ENAP is unusual in being a partial releaser of serotonin and dopamine and a full releaser of norepinephrine.
6-AB, also known as 6-amino-6,7,8,9-tetrahydro-5H-benzocycloheptene, is a conformationally restricted analogue of amphetamine related to 2-aminoindane (2-AI) and 2-aminotetralin (2-AT). Unlike amphetamine, 2-AI, and 2-AT, 6-AB did not produce stimulant-type effects in animals. In another study, it produced a biphasic effect at high doses, with initial hypolocomotion followed after a few hours by weak locomotor stimulation. 7-AB is a positional isomer of 6-AB.
The side chain conformations of various phenylisopropylamines have been studied by nuclear magnetic resonance, and suggest that in solution, an extended trans-phenylamino arrangement is preferred.29 Some of the conformationally restricted analogs of phenylalkylamines mimic this conformation.29 For example 2-aminotetralin (2-AT, 17) mimics this to some extent, while 2-aminoindane (2-AI, 18) to a lesser extent. It was found that 2-AI (18) and in particular 2-AT (17) are capable of producing various amphetamine-like effects, including anorexia and locomotor stimulation in animals.29 Four conformationally restricted analogs, 2-AI (18), 2-AT (17), 6-amino- and 7-amino-6,7,8,9-tetrahydro-5H-benzocycloheptene (6-AB, 19 and 7-AB, 20, respectively) were studied and it was found that 2-AT (17) is most similar to racemic amphetamine in potency and may be the conformation that best mimics amphetamine necessary for producing amphetamine-like stimulant effects, however, compounds 19 and 20 failed to produce amphetamine-like stimulant effect.29 The racemic aminotetralin 17 produced 10% the locomotor stimulant action of amphetamine in mice, whereas 18 was inactive at the highest doses tested.21
Both 6-amino- and 7-amino-6,7,8,9-tetrahydro-5H-benzocycloheptene, 6-AB and 7-AB, [...]. Stimulus generalization was not observed to occur with phenethylamine, 1-NAP, 2-NAP, 1-PP, 6-AB, 7-AB, or α-demethylcathinone (Table 1). [...] 6-AB produced saline-appropriate responding at doses of up to 20 mg/kg, whereas 7-AB produced similar responding at 17.5 mg/kg and disruption of behavior at 20 and 25 mg/kg. All four animals treated with 25 mg/kg of 7-AB died within 24 hours of administration of drug. [...] Most of the agents employed in this study have been previously examined for amphetamine-like properties. For example, 2-AI and 2-AT produce anorectic effects in animals, with 2-AI apparently being the more active [23]. Phenethylamine, 1-NAP and 2-NAP are inactive as locomotor stimulants in rodents; while 2-AI and 2-AT produce locomotor stimulation, both are less active than amphetamine [23,31]. At high doses, 6-AB produces a biphasic effect, an initial locomotor depressant action followed, after approximately two to three hours, by weak locomotor stimulation [32]. [...] 2-AT is more active than 2-AI in producing rotational behavior in 6-hydroxydopamine-lesioned rats, while 6-AB is inactive at 10 mg/kg [3]. [...]